Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ASCO Highlights In Brief

Executive Summary

Amgen's Prolia: Data presented at the American Society of Clinical Oncology meeting in Chicago included new information on the use of Amgen's RANK ligand inhibitor, Prolia (denosumab), in delaying skeletal related events in prostate cancer patients with bone metastases. The study met its primary and secondary endpoints showing superiority in a head-to-head trial against Novartis' Zometa (zoledronic acid) in postponing time to the first SRE by 20.7 months compared to 17.1 months. Overall, the data were inline with the expectations of analysts, who remain bullish on the compound in the wake of its approval in the post-menopausal osteoporosis setting and Amgen's decision to price the compound aggressively (1"The Pink Sheet," June 7, 2010). The study was typical of Amgen's showing at the June 4-7 cancer meeting, which was generally positive but incremental

You may also be interested in...

Prolia Pricing: Straddling Osteoporosis And Oncology

Amgen's first-in-class Prolia (denosumab) is burdened with a high price point as it joins the competitive and price-sensitive osteoporosis market. With a wholesale acquisition cost of $1,650 a year - including two $825 injections - Prolia will officially cost more than the leading branded drugs Actonel (risedronate), Boniva (ibandronate) and Reclast (zoledronic acid), and it will have to compete against generic versions of the gold standard, alendronate (Merck's Fosamax)

In Obtaining Strong Price From BMS, Medarex Also Ameliorates Significant Pipeline Pressure

Bristol's acquisition offer of $16 per share is certainly generous, but Medarex has a lengthy and promising pipeline to offer and one which would have needed deep pockets down the road.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts